ArticleFrontiers in public health2025
Association between vaccination uptake, vaccine type, and long COVID in rural Indonesia.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Long COVID affects a significant proportion of individuals after SARS-CoV-2 infection. While vaccines reduce severe disease, their effect on long COVID remains unclear, especially in rural, resource-limited settings. This study investigates the association between vaccination status, vaccine type, and long COVID in Malang Regency, East Java. Methods: We analysed cross-sectional data from 5,735 adults who tested positive for COVID-19 between June 2022 and June 2023. Long COVID was defined as persistent symptoms ≥12 weeks post-infection. Data on vaccination status, vaccine type, comorbidities, and sociodemographic characteristics were collected through surveys and linked to immunisation records. Multivariable logistic regression was used to estimate adjusted odds ratios (aORs) for long COVID, including stratified analyses by vaccine platform and dose. Results: Long COVID was reported by 56.2% of participants. Compared to unvaccinated individuals, those who received mRNA vaccines had significantly lower odds of long COVID, Moderna (OR = 0.341, 95% CI: 0.067-0.887) and Pfizer (OR = 0.220, 95% CI: 0.057-0.771), while recipients of non-mRNA vaccines, such as Sinovac (OR = 1.205, 95% CI: 1.038-1.331), had increased odds. A dose-response relationship was observed for mRNA vaccines, with two doses (OR = 0.420, 95% CI: 0.402-0.511) and three or more doses (OR = 0.743, 95% CI: 0.601-0.712) both reducing risk compared to no mRNA vaccination. Older age, hypertension, higher education, and higher income were also associated with increased long COVID risk. Conclusion: mRNA COVID-19 vaccines and full vaccination schedules are strongly protective against long COVID in rural Indonesia. These findings highlight the need to improve access to mRNA vaccines and booster doses to reduce long-term COVID-19 impacts in underserved populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.